Bone-site-specific responses to zoledronic acid.

Abstract

Bisphosphonates are widely used to treat bone diseases such as osteoporosis. However, they may cause osteonecrosis of the jaw. Here, we investigated whether invivo exposure to bisphosphonates has a different effect on long bone and jaw osteoclasts, and on the turnover of these different bones. Zoledronic acid (0.5mgkg-1 weekly) was administered intraperitoneally to 3-month-old female mice for up to 6months. The effects on the number of osteoclasts, bone mineralization and bone formation were measured in the long bones and in the jaw. Long-term treatment with zoledronic acid reduced the number of jaw bone marrow cells, without affecting the number of long bone marrow cells. Zoledronic acid treatment did not affect the number of osteoclasts invivo. Yet, the bisphosphonate increased bone volume and mineral density of both long bone and jaw. Interestingly, 6months of treatment suppressed bone formation in the long bones without affecting the jaw. Unexpectedly, we showed that bisphosphonates can cause molar root resorption, mediated by active osteoclasts. Our findings provide more insight into bone-site-specific effects of bisphosphonates and into the aetiology of osteonecrosis of the jaw. We demonstrated that bisphosphonates can stimulate osteoclast activity at the molar roots.